Jim Cramer on Thermo Fisher: "They Really Got Hurt By COVID"

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the stocks Jim Cramer put under the microscope. When Cramer was asked about the stock, he commented:

“Oh yeah… they really got hurt by COVID. I gotta tell you, as good as Marc Casper is at Thermo Fisher, I’m still saying that Danaher’s better. They’ve both been in the same junk heap, and they shouldn’t have been. Danaher, I think, has got more going for it right now than Thermo Fisher. I would do DHR. That’s a club name.”

Thermo Fisher Scientific Inc. (NYSE:TMO) provides life sciences solutions, analytical instruments, diagnostics, lab products, and biopharma services. When a caller inquired about the stock in the June 27 episode, Cramer responded:

“This stock is unbelievable. It was a, it’s a great company. Marc Casper does a terrific job, but we own Danaher for the Charitable Trust, and it’s as bad as Thermo Fisher. I am urging you to not buy it till we see a pickup in Chinese orders. I know that seems strange, but this stock has crushed a lot of people. It does seem like it’s bottoming, but I am not going to push it because it’s related to China, and anything related to China is bearish.”

While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.